Second hematologic malignancies after ABVD: Two case reports and a retrospective study of 183 Hodgkin lymphoma patients

Acta Oncologica

Volumn 49, Issue 2, 2010, Pages 257-259

  Leong, Carrie ^a   Ngeow, Joanne ^a   Tan, Iain ^a   Quek, Richard ^a   Tao, Miriam ^a   Loh, Yvonne ^b   Tan, Huey Ching ^a   Lim, Soon Thye ^a  

^a DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^b SINGAPORE GENERAL HOSPITAL   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CHLORMETHINE; CYTARABINE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; IDARUBICIN; PREDNISOLONE; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE; VINCRISTINE SULFATE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; CANCER RADIOTHERAPY; CANCER RISK; HEMATOLOGIC MALIGNANCY; HODGKIN DISEASE; HUMAN; LARGE CELL LYMPHOMA; LETTER; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SECOND CANCER;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; DACARBAZINE; DOXORUBICIN; HODGKIN DISEASE; HUMANS; LEUKEMIA, MYELOID, ACUTE; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; VINBLASTINE;

EID: 76649112752     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/02841860903253546     Document Type: Letter

References (11)

1. Boivin JF, Hutchison GB, Zauber AG, Bernstein L, Davis FG, Michel RP, et al. Incidence of second cancers in patients treated for Hodgkin's disease. J Natl Cancer Inst 1995;87:732-41.
2. Kaldor JM, Day NE, Clarke EA, van Leeuwen FE, Henry-Amar M, Fiorentino MV, et al. Leukemia following Hodgkin's disease. N Engl J Med 1990;322:7-13.
3. Swerdlow AJ, Barber JA, Hudson GV, Cunningham D, gupta RK, Hancock BW, et al. Risk of second malignancy after Hodgkin's disease in a collaborative British cohort: The relation to age at treatment. J Clin Oncol 2000;18:498-509.
4. Josting A, Wiedenmann S, Franklin J, May M, Sieber M, wolf J, et al. The German Hodgkin's Lymphoma Study Group. Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: A report from the German Hodgkin's Lymphoma Study Group. J Clin Oncol. 2003;21:3440-6. Epub 2003 Mar 7.
5. van Leeuwen FE, Klokman WJ, Hagenbeek A, Noyon R, van den Belt-Dusebout AW, van Kerkhoff EH, et al. Second cancer risk following Hodgkin's disease: A 20-year follow-up study. J Clin Oncol 1994;12:312-25.
6. Tucker MA, Coleman CN, Cox RS, varghese A, Rosenberg SA. Risk of second cancers after treatment for Hodgkin's disease. N Engl J Med. 1988;318:76-81.
7. Abrahamsen JF, Andersen A, Hannisdal E, Nome O, Abrahamsen AF, Kvaløy S, et al. Second malignancies after treatment of Hodgkin's disease: The infuence of treatment, follow-up time, and age. J Clin Oncol. 1993;11:255-61.
8. Munker R, grützner S, Hiller E, Aydemir U, Enne W, Dietzfelbinger H, et al. Second malignancies after Hodgkin's disease: The Munich experience. Ann Hematol 1999;78:544-54.
9. Dietrich PY, Henry-Amar M, Cosset JM, Bodis S, Bosq J, Hayat M. Second primary cancers in patients continuously disease-free from Hodgkin's disease: A protective role for the spleen? Blood 1994;84:1209-15.
10. Mauch PM, Kalish LA, Marcus KC, Coleman CN, Shulman LN, Krill E, et al. Second malignancies after treatment for laparotomy staged IA-IIIB Hodgkin's disease:Long-term analysis of risk factors and outcome. Blood. 1996;87:3625-32.
11. Seow A, Koh WP, Shi LM, Lee HP, Shanmugaratnam K. Trends in cancer incidence in Singapore 1968-2002; Singapore Cancer registry report Number 6.